March 29 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* Aurinia announces result from data and safety monitoring board for its phase 2b study in lupus nephritis - study to continue as planned
* Says dsmb has again recommended that the study continue as planned without
any modifications
* Source text for Eikon Further company coverage AUP.TO